Corticosteroids

Clinics in Dermatology

Volumn 15, Issue 5, 1997, Pages 715-721

  Hughes, Jenny ^a   Rustin, Malcolm ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 HYDROXYCORTICOSTEROID; ANTIINFECTIVE AGENT; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CLOBETASOL PROPIONATE; CLOBETASONE BUTYRATE; COAL TAR; COLLAGEN; CORTICOSTEROID; CORTICOTROPIN; CYTOKINE; DITHRANOL; DNA; ELASTIN; FLUOCINOLONE ACETONIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID RECEPTOR; HALCINONIDE; HEAT SHOCK PROTEIN; HYDROCORTISONE; MOMETASONE FUROATE; PROPYLENE GLYCOL; PSORALEN; RETINOID; SALICYLIC ACID DERIVATIVE; TETRACOSACTIDE; TIXOCORTOL PIVALATE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; UREA;

ACNE; ADRENAL INSUFFICIENCY; CLINICAL TRIAL; CUSHING SYNDROME; DILUTION; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; GENETIC TRANSCRIPTION; HUMAN; HYPERTRICHOSIS; HYPOPHYSIS ADRENAL SYSTEM; NONHUMAN; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PUVA; REVIEW; SKIN ALLERGY; SKIN ATROPHY; TOPICAL DRUG ADMINISTRATION; VASOCONSTRICTION;

EID: 0030864015     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(97)00020-5     Document Type: Article

References (29)

1. Elks J. Steroid structure and steroid activity. Br J Dermatol 1976,-94(suppl 12):3-13.
2. Sulzberger MB, Witten VH. The effect of topically applied Compound F in selected dermatoses. J Invest Dermatol 1952;19:101-2.
3. Mackenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol 1964; 86:608-10.
4. Cornell RC. Clinical trials of topical corticosteroids in psoriasis: Correlations with the vasoconstrictor assay. Int .1 Dermatol 1992;31(suppl):38-40.
5. Kathchman SD, Del Monaco M, Wu M, et al. A transgenic mouse model provides a novel biological assay of topical glucocorticosteroid potency. Arch Dermatol 1995;131: 1274-8.
6. Oakley RH, Cidlowski JA. Homologous down-regulation of the glucocorticoid receptor: The molecular machinery. Crit Rev Eukaryot Gene Expr 1993;3:63-88.
7. Scheinman RI, Cogswell PG, Lofquist AK, et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270:283-6.
8. Almawi WY, Lipman ML, Stevens AC, et al. Abrogation of glucocorticosteroid-mediated inhibition of T-cell proliferation by the synergistic action of IL-1, IL-6, and IFN. J Immunol 1991;146:3523-7.
9. Wright S. Steroids and their mechanism of action. Proc R Coil Phys Edin 1995;25:34-9.
10. Pershing LK, Silver BS, Krueger GG, et al. Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay. Pharmacol Res 1992;9:45-51.
11. Broby-Johansen U, Karlsmark T, Petersen LJ, et al. Ranking of the antipsoriatic effect of various topical corticosteroids applied under a hydrocolloid dressing-Skin-thickness, blood-flow and colour measurements compared to clinical assessments. Clin Exp Dermatol 1990;15:343-8.
12. Katz HI, Hien NT, Prawer SE, et al. Betamethasone in optimized vehicle. Intermittent pulse dosing for extended maintenance treatment of psoriasis. Arch Dermatol 1987; 123:1308-11.
13. Pershing LK, Corlett JL, Lambert LD, et al. Circadian activity of topical 0.05% betamethasone dipropionate in human skin in vivo. J Invest Dermatol 1994;102:734-9.
14. Degreef H, Doorns-Goossens A. The new corticosteroids: Are they effective and safe? Dermatol Clin 1993;11:155-60.
15. Medansky RS, Bressinck R, Cole GW, et al. Mometasone furoate ointment and cream 0.1% in treatment of psoriasis: Comparison with ointment and cream formulations of fluocinolone acetonide 0.025% and triamcinolone 0.1%. Cutis 1988;42:480-5.
16. Rosenthal D, Duke E. A clinical investigation of the efficacy and safety of mometasone furoate ointment 0.1% vs betamethasone valerate ointment 0.1% in the treatment of psoriasis. Curr Ther Res 1988;44:790-800.
17. Chu AC, Munn S. Fluticasone propionate in the treatment of inflammatory dermatoses. Br J Clin Pract 1995;49:131-3.
18. Gallen J. Comparison of safety and efficacy of fluticasone propionate cream 0.05% and betamethasone valerate cream 0.1% in the treatment of moderate-to-severe psoriasis. Cutis 1996;57:45-50.
19. Giannotti B, Pimpinelli N. Topical corticoids: Which drug and when? Drugs 1992;44:65-71.
20. Meola T Jr, Soter NA, lim HW. Are topical corticosteroids useful adjunctive therapy for the treatment of psoriasis with ultraviolet radiation? Arch Dermatol 1991;127:1708-13.
21. Fritsch PO. Retinoids in psoriasis and disorders of keratinization. J Am Acad Dermatol 1992;27:S8-14.
22. Kerscher MJ, Korting HC. Comparative atrophogenicity potential of medium and highly potent topical glucocorticoids in cream and ointment according to ultrasound analysis. Skin Pharmacol 1992;5:77-80.
23. Lauerma AI, Reitamo S. Contact allergy to corticosteroids. J Am Acad Dermatol 1993;28:618-22.
24. Boffa MJ, Wilkinson SM, Beck MI. Screening for cortico-steroid hypersensitivity. Contact Dermatitis 1995;35:149-51.
25. Coopman S, Degreef H, Dooms-Goossens A. Identification of cross-reaction patterns in allergic contact dermatitis from topical corticosteroids. Br J Dermatol 1989;121:27-34.
26. Katz HI, Hien N, Prawer SE, et al. Superpotent topical steroid treatment of psoriasis vulgaris - Clinical efficacy and adrenal function. J Am Acad Dermatol 1987;16:804-11.
27. Teelucksingh S, Bahall M, Coomansingh D, et al. Cushing's syndrome from topical glucocorticids. W Indian Med J 1993;42:77-8.
28. Ryan TJ, Baker H. Systemic corticosteroids and folic acid antagonists in the treatment of generalised pustular psoriasis. Evaluation and prognosis based on the study of 104 cases. Br J Dermatol 1969;81:134-45.
29. Lotem M, Katzenelson V, Rotem A, et al. Impetigo herpetiformis: A variant of pustular psoriasis or a separate entity? J Am Acad Dermatol 1989;20:338-41.